acut
respiratori
infect
ari
preval
worldwid
infect
influenza
viru
particularli
respons
morbid
mortal
among
children
group
consid
high
risk
complic
viral
infect
publish
studi
preval
viral
respiratori
infect
juvenil
idiopath
arthriti
jia
patient
known
patient
higher
risk
sever
influenza
infect
compar
healthi
children
studi
suggest
ari
trigger
jia
avail
evid
suggest
influenza
vaccin
safe
immunogen
children
jia
howev
known
influenza
vaccin
actual
protect
influenzalik
ill
ili
object
studi
evalu
frequenc
ari
ili
jia
patient
affect
diseas
activ
assess
immunogen
safeti
efficaci
influenza
vaccin
jia
patient
treat
potenti
immunosuppress
drug
includ
perform
longitudin
prospect
surveil
studi
ari
ili
episod
influenza
vaccin
cohort
jia
patient
classifi
intern
leagu
rheumat
ilar
criteria
attend
tertiari
pediatr
rheumatolog
clinic
surveil
occur
month
peak
occurr
ari
two
consecut
year
march
august
surveil
march
august
surveil
nineti
elig
jia
patient
particip
patient
lost
follow
patient
abl
attend
regular
visit
due
home
distanc
hospit
sixtythre
patient
particip
period
patient
particip
new
jia
patient
old
patient
return
follow
period
figur
influenza
vaccin
offer
april
juli
jia
patient
attend
clinic
agre
particip
patient
least
one
follow
criteria
exclud
vaccin
presenc
system
symptom
fever
rash
vascul
hepatosplenomegali
seros
vaccin
vaccin
previou
month
allergi
compon
influenza
vaccin
previou
histori
guillainbarr
syndrom
ten
healthi
children
year
receiv
influenza
vaccin
order
evalu
immunogen
specif
batch
vaccin
routin
clinic
evalu
includ
pediatr
american
colleg
rheumatolog
conduct
surveil
period
prior
day
influenza
vaccin
jia
flare
defin
worsen
least
two
six
criteria
acrp
index
simultan
improv
one
criterion
consid
relat
ari
ili
occur
day
ari
ili
episod
diseas
activ
defin
presenc
least
one
joint
activ
arthriti
system
sign
symptom
fever
rash
vascul
hepatosplenomegali
seros
studi
protocol
approv
ethic
committe
hospit
da
da
faculdad
de
medicina
de
pretousp
process
number
parent
children
adolesc
involv
studi
gave
inform
consent
particip
ari
episod
defin
presenc
one
respiratori
symptom
rhinorrhea
sneez
nasal
obstruct
hoars
stridor
cough
dyspnea
tachypnea
chest
retract
wheez
rhonchi
case
ili
defin
presenc
fever
plu
least
one
respiratori
symptom
cough
andor
sore
throat
one
constitut
symptom
headach
malais
myalgia
sweat
chill
fatigu
contact
patient
made
telephon
everi
two
three
week
routin
visit
patient
also
instruct
contact
medic
staff
case
respiratori
symptom
clinic
assess
diseas
activ
includ
laboratori
test
carri
follow
clinic
routin
observ
period
medic
record
analyz
retrospect
identifi
possibl
tempor
associ
day
ariili
episod
sign
worsen
underli
diseas
two
studi
period
patient
ari
andor
ili
nasopharyng
swab
collect
viral
detect
within
first
hour
symptom
accord
recommend
procedur
attack
rate
express
ari
episod
per
childday
risk
childday
consid
day
studi
child
cohort
calcul
attack
rate
atrisk
childday
includ
denomin
remov
day
contain
within
ari
subsequ
day
nasopharyng
swab
collect
nostril
immers
viral
transport
medium
vtm
immedi
transport
ice
viral
pathogenesi
laboratori
virolog
research
center
univers
paulo
school
medicin
preto
sampl
frozen
test
realtim
pcr
presenc
influenza
b
respiratori
syncyti
viru
hrsv
b
metapneumoviru
hmpv
parainfluenza
viru
hpiv
bocaviru
hbov
adenoviru
hadv
rhinoviru
hrv
coronaviru
e
hcov
nucleic
acid
extract
sampl
use
qiaamp
minelut
viru
spin
kit
qiagen
hilden
germani
follow
manufactur
instruct
detect
respiratori
virus
perform
realtim
pcr
qpcr
use
taqman
strategi
appli
biosystem
specif
primer
probe
addit
file
thermocycl
appli
biosystem
qpcr
housekeep
gene
done
sampl
intern
control
qpcr
hrsva
b
hcov
two
set
hrv
serotyp
hadv
hbov
done
duplex
format
wherea
singl
qpcr
one
pair
primer
per
reaction
done
hmpva
hmpvb
influenza
influenza
b
rna
virus
hrv
influenza
hpiv
hrsv
hmpv
hcov
revers
transcript
done
prior
pcr
use
multiscrib
revers
transcriptas
appli
biosystem
rna
prime
random
hexam
follow
protocol
propos
manufactur
detail
addit
file
trival
split
influenza
vaccin
contain
asolomon
bflorida
sanofi
pasteur
sabutantan
institut
recommend
use
southern
hemispher
given
patient
healthi
children
march
may
patient
healthi
children
older
year
receiv
one
intramuscular
dose
vaccin
ml
yearold
patient
receiv
two
dose
ml
ml
respect
week
apart
follow
establish
recommend
local
symptom
inject
site
system
symptom
record
antiinfluenza
antibodi
titer
determin
hemagglutin
inhibit
hi
prior
day
post
vaccin
respiratori
virus
laboratori
evandro
chaga
institut
accord
standard
procedur
serum
sampl
store
test
treat
receptordestroy
enzym
turkey
red
blood
cell
remov
nonspecif
agglutinin
serum
sampl
test
hi
antibodi
three
antigen
includ
vaccin
work
dilut
test
dose
antigen
contain
four
hi
unit
test
dose
dilut
phosphatebuff
salin
ad
serial
dilut
antiserum
hi
titer
determin
reciproc
last
serum
dilut
complet
inhibit
red
blood
cell
agglutin
titer
serum
show
inhibit
dilut
assign
valu
rise
titer
rise
titer
consid
signific
respons
vaccin
hi
titer
indic
protect
infect
geometr
mean
titer
gmt
calcul
use
logtransform
titer
valu
protect
rate
exceed
vaccin
group
seroconvers
rate
exceed
seroconvers
factor
exceed
consid
cutoff
level
vaccin
immunogen
accord
guidelin
european
committe
proprietari
medicin
product
cpmp
assess
influenza
vaccin
adult
statist
analysi
carri
use
system
version
sa
institut
inc
compar
frequenc
episod
ari
ili
worsen
indic
diseas
activ
period
surveil
vaccin
unvaccin
patient
data
fit
zeroinfl
poisson
model
multipl
model
comparison
ari
ili
episod
adjust
covari
jia
type
onset
oligoarticular
polyarticular
system
gender
age
year
old
year
old
diseas
activ
use
immunosuppress
therapi
perform
student
test
use
compar
geometr
mean
hi
titer
calcul
perform
logtransform
valu
base
fisher
exact
test
use
evalu
associ
respons
rate
vaccin
antigen
patient
group
differ
therapeut
regimen
methotrexateleflunomid
inhibitor
differ
agegroup
yr
yr
jia
onset
type
oligoarticular
polyarticular
system
patient
activ
diseas
logist
regress
model
adjust
covari
perform
evalu
influenc
seroconvers
comparison
variabl
relat
diseas
activ
vaccin
nonparametr
friedman
test
use
test
signific
level
adopt
demograph
jia
clinic
characterist
patient
summar
tabl
two
surveil
period
ari
episod
report
patient
patient
evalu
data
childday
childday
day
respect
contain
within
ari
ari
mean
day
day
subsequ
notatrisk
day
leav
day
atrisk
childday
includ
first
day
ari
respect
give
attack
rate
confid
interv
ci
ari
per
childday
respect
twentyeight
episod
character
ili
ari
ili
episod
significantli
frequent
p
even
adjust
jia
type
onset
age
younger
older
year
diseas
activ
use
immunosuppress
dmard
administr
influenza
vaccin
signific
differ
p
frequenc
ari
episod
vaccin
unvaccin
patient
howev
ili
episod
significantli
common
unvaccin
patient
p
although
differ
maintain
adjust
variabl
describ
p
nasopharyng
sampl
collect
studi
posit
least
one
respiratori
viru
viral
coinfect
detect
posit
sampl
tabl
consid
total
ili
episod
report
posit
influenza
sampl
obtain
ili
episod
ili
episod
patient
includ
prior
influenza
vaccin
although
commonli
detect
viru
ili
episod
influenza
detect
hpiv
hadv
detect
one
ili
episod
tabl
patient
ari
ili
favor
outcom
except
one
patient
develop
acut
otiti
media
pneumonia
ili
episod
caus
hpiv
infect
studi
jia
flare
worsen
jia
activ
paramet
observ
patient
includ
least
one
two
surveil
period
tempor
associ
respiratori
infect
episod
classifi
ili
episod
could
identifi
trigger
factor
possibl
associ
flare
tabl
possibl
factor
associ
jia
flare
episod
relat
respiratori
infect
suspens
nonadhear
medic
twelv
episod
intercurr
infect
seven
episod
otiti
chickenpox
parotid
gastroenterocol
infect
sacroili
twelveon
episod
identifi
caus
flare
signific
differ
total
number
flare
relat
gender
age
year
old
year
old
jia
type
onset
oligoarticular
polyarticular
system
use
immunosuppress
therapi
period
surveil
administr
influenza
vaccin
flare
worsen
jia
activ
paramet
associ
ari
frequent
observ
patient
system
jia
flare
occur
group
compar
patient
polyarticular
jia
flare
p
prevaccin
geometr
mean
titer
gmt
confid
interv
ci
bflorida
jia
patient
respect
post
vaccin
period
vaccin
respons
patient
control
describ
tabl
thirtyon
patient
receiv
influenza
vaccin
use
methotrex
leflunomid
one
patient
cyclosporin
five
receiv
drug
time
vaccin
six
patient
use
corticosteroid
mean
daili
dose
mgkgday
mean
durat
treatment
month
gener
respons
influenza
vaccin
influenc
age
jia
type
onset
therapeut
regimen
diseas
activ
patient
drug
present
lower
seroconvers
p
seroprotect
respons
strain
seroprotect
cutoff
level
strain
bflorida
vaccin
consid
safe
pain
inject
site
describ
jia
patient
healthi
children
local
chang
red
swell
warmth
report
jia
patient
healthi
children
six
patient
develop
cough
rinorrhea
without
fever
first
ten
day
receiv
vaccin
signific
differ
found
jia
activ
index
dose
prednison
use
patient
day
vaccin
p
tabl
methotrex
weekli
dose
significantli
lower
day
vaccin
compar
pre
vaccin
dose
p
patient
report
ili
symptom
postvaccin
followup
period
far
know
publish
studi
evalu
frequenc
impact
ari
ili
jia
patient
observ
attack
rate
ari
per
childday
respect
similar
ari
rate
previous
report
healthi
children
age
viral
agent
detect
episod
sampl
studi
influenza
hrv
frequent
detect
virus
studi
conduct
tropic
countri
hrv
test
frequent
identifi
viru
influenza
detect
rang
posit
sampl
differ
studi
design
viru
detect
assay
may
explain
differ
frequenc
viru
detect
viral
dual
infect
detect
posit
sampl
studi
hrv
identifi
coinfect
also
detect
studi
rang
posit
sampl
evalu
ili
episod
correspond
ari
episod
influenza
frequent
detect
viru
hpiv
hadv
also
detect
studi
also
call
attent
fact
influenza
detect
ili
episod
brazil
studi
show
ari
episod
classifi
ili
influenza
account
hrv
detect
ili
episod
therefor
difficult
estim
influenza
vaccin
efficaci
base
clinic
analysi
ili
episod
frequenc
clinic
pattern
ari
patient
chronic
diseas
poorli
studi
respiratori
virus
detect
febril
episod
occur
children
leukemia
frequenc
ari
children
cystic
fibrosi
control
surveil
period
similar
morbid
infect
higher
patient
cystic
fibrosi
studi
viral
infect
includ
influenza
infect
satisfactori
outcom
jia
patient
one
patient
acut
otiti
media
pneumonia
associ
hpiv
despit
outcom
viral
infect
studi
similar
healthi
popul
result
suggest
viral
ari
ili
may
associ
jia
exacerb
flare
episod
flare
worsen
diseas
activ
observ
studi
period
ten
happen
along
within
week
viral
ari
hrsv
hadv
hpiv
hmpv
influenza
virus
detect
associ
flare
studi
address
possibl
relationship
viral
ari
jia
recent
toplak
et
report
jia
relaps
ili
episod
present
studi
jia
flare
worsen
jia
activ
paramet
tempor
associ
know
trigger
way
imposs
determin
whether
coincident
causal
relationship
ari
jia
flare
specul
ari
may
role
worsen
episod
anoth
interest
find
studi
major
flare
associ
viral
infect
occur
patient
system
onset
jia
also
assess
safe
immunogen
effect
influenza
vaccin
prospect
opencohort
studi
suggest
influenza
vaccin
safe
associ
diseas
activ
autoantibodi
induct
studi
patient
follow
period
vaccin
signific
side
occur
includ
flare
diseas
immunogen
influenza
vaccin
jia
patient
previous
look
malleson
et
al
evalu
immunogen
influenza
vaccin
children
chronic
arthriti
healthi
control
differ
antibodi
titer
vaccin
observ
children
chronic
arthriti
control
among
patient
treat
dmard
andor
prednison
kanadouditsakalid
et
al
evalu
jia
patient
also
show
satisfactori
vaccin
immunogen
effect
ili
episod
observ
sixmonth
period
vaccin
ogimi
et
al
evalu
children
jia
found
differ
seroconvers
rate
compar
gender
age
vaccin
dosag
prednisolon
dosag
use
immunosuppress
logist
regress
analysi
studi
first
evalu
influenza
vaccin
seroconvers
one
patient
jia
treatment
antitnf
immunogen
safeti
epidem
influenza
vaccin
studi
patient
autoimmun
rheumat
diseas
ard
jia
healthi
control
author
demonstr
reduc
immun
respons
vaccin
ard
patient
compar
control
found
glucocorticoid
use
major
factor
decreas
antibodi
product
immunogen
influenza
vaccin
recent
investig
patient
systemiconset
juvenil
idiopath
arthriti
receiv
tocilizumab
receptor
antibodi
author
observ
highdos
prednisolon
tocilizumab
impair
product
influenza
antibodi
patient
toplak
et
recent
show
adequ
respons
influenza
vaccin
jia
patient
except
subgroup
children
receiv
antitnf
therapi
observ
differ
rate
influenza
infect
jia
patient
healthi
children
follow
month
vaccin
studi
immunogen
influenza
vaccin
found
satisfactori
found
influenc
age
jia
type
onset
activ
diseas
use
prednisolon
methotrex
seroconvers
rate
subgroup
patient
use
anti
tnf
alpha
show
lower
seroconvers
rate
strain
sampl
size
present
studi
small
possibl
assess
adjust
odd
ratio
use
antitnf
alpha
relat
variabl
studi
children
inflammatori
bowel
diseas
show
patient
receiv
antitnf
therapi
less
like
seroprotect
b
strain
dell
era
et
al
recent
evalu
administr
immunogen
adjuv
influenza
vaccin
season
vaccin
could
overcom
problem
possibl
impair
antibodi
product
jia
patient
treat
etarnecept
safeti
toler
vaccin
satisfactori
result
studi
indic
reduc
immun
respons
vaccin
jia
children
adolesc
treat
etanercept
comparison
dmard
healthi
control
first
studi
assess
effect
influenza
vaccin
thorough
surveil
vaccin
unvaccin
patient
influenza
season
period
signific
differ
frequenc
ari
episod
vaccin
episod
classifi
ili
common
unvaccin
patient
differ
maintain
adjust
covari
surveil
period
age
immunosuppress
use
activ
diseas
believ
failur
maintain
signific
episod
vaccin
patient
relat
small
sampl
size
sinc
identifi
specif
covari
respons
failur
perform
multipl
model
analysi
thu
possibl
prove
vaccin
realli
effect
influenza
infect
pattern
season
influenza
infect
seem
differ
two
surveil
period
howev
import
state
followup
period
six
month
vaccin
none
vaccin
patient
ili
episod
infect
caus
common
respiratori
virus
may
associ
jia
flare
hypothesi
address
larger
epidemiolog
studi
trival
split
influenza
vaccin
seem
immunogen
safe
effect
children
adolesc
jia
despit
use
immunosuppress
agent
activ
diseas
studi
larger
number
patient
treat
blocker
necessari
order
verifi
whether
lower
vaccin
respons
occur
group
patient
compet
interest
author
work
lc
ea
vf
contribut
design
studi
lc
vf
particip
interview
chart
revis
lc
lr
perform
data
studi
sampl
collect
analysi
interpret
fp
carri
realtim
pcr
viral
detect
analysi
interpret
data
rs
wm
lc
carri
hemagglutin
inhibit
assay
detect
antiflu
antibodi
analysi
interpret
data
lc
wrote
manuscript
ea
vf
help
revis
suggest
author
read
approv
final
manuscript
